Clinical Trial Search

Primary: Global Response Assessment (GRA) Responders at Week 11. — 19; 15 participants

Primary: Safety as Measured by the Number of Participants With Adverse Events — 9 participants

Primary: Change From Baseline in Averaged Postprandial Glucose in Response to a MMT Test — 0.16; -0.44; -1.10; 0.51 mmol/L

Primary: Count/Percentage of Patients Progression-free at 6 Months for Bevacizumab and Irinotecan Hydrochloride Arm — 22 Participants

Primary: Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 3 Strains of Influenza Virus — 13.4; 13.9; 14.2; 10.8 titer

Primary: Response Rate (Partial and Complete Response) in Patients With or Without ASS Expression Present in Tumor. — 0; 4 participants

Primary: Percentage of Participants With Virologic Response at Week 12 — 92.5; 88.1; 92.5; 87.2 Percentage of participants

Primary: Change From Baseline in Mean Duration of the QTc Interval — 1.2; -1.0; -4.0; -0.1 milliseconds

Primary: Percentage of Patients With a 2-deoxy-2-[18F]Fluoro-D-glucose-positron Emission Tomography (FDG-PET) Response at Day 56 in All Patients and in Epidermal Growth Factor…

Primary: Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 3 Strains of Influenza Disease. — 13.0; 12.3; 12.9; 14.9 titers

Primary: Number of Patients With Complete Response (CR) — 1; 13 participants

Primary: Number of Subjects With Any and Grade 3 Solicited Local Symptoms. — 2; 14; 0; 1 subjects

Primary: Change From Baseline in Size of Geographic Atrophy Lesion Area in the Study Eye — 6.219; 6.897; 5.526; 0.898 Disc Area

Primary: Prolonged Smoking Abstinence: 4 Weeks Post Quit-Date — 43; 29; 40; 39 Participants

Primary: Sedative Exposure — 1; 7; 6 exposures/4-hours per day